02 June 2023>: Clinical Research
Differences in Outcomes Between Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Patients in Upper Middle-Income versus High-Income Countries: A Retrospective Study from 4 Oncology Centers
Dragana Miletić 1ADEF* , Marija Kraljević 1ADEF , Emir Sokolović 2CDE , Majana Soče 3B , Marijana Milović-Kovačević 4B , Simonida Bobić 4B , Timur Cerić 2ABDE , Stjepko Pleština 3A , Semir Bešlija 2AE , Inga Marijanović 15ADEDOI: 10.12659/MSM.940356
Med Sci Monit 2023; 29:e940356
Figure 10 Overall survival (OS) of patients with metastatic HER2-positive breast cancer in 4 oncology centers in high-income and upper-middle-income countries according to second-line treatment (regimen with trastuzumab emtansine vs other regimens).